Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(i) To analyze the expression of MCM2 in cervical cancer; (ii) to correlate MCM2 expression with the clinical tumor staging according to FIGO classification, and (iii) to relate HPV type to MCM2 expression.
|
24706378 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor tissue was examined histologically for presence of the KRAS mutations and for expression of hypoxia-inducible factor-1 (HIF-1) and minichromosome maintenance protein 2 (mcm2).
|
24516257 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCM2 (p=0.006), Ki67 antigen (p=0.035) and p53 expression (p=0.049) as well as tumor grade (p=0.026) and age (p=0.025) were found significantly associated with recurrence-free survival by univariate Cox regression analysis, among which only Ki67 antigen expression (p=0.015) and age (p=0.019) proved to be of independent predictive value by multivariate analysis.
|
12565771 |
2003 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCM2-7 and MCM10 expressions were associated with WHO tumor grade.
|
25046975 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As MCM2 appears to be an attractive alternative to Ki-67, we sought to study the expression of MCM2 and Ki-67 in different histological grades and molecular subtypes of breast cancer focusing primarily on ER-positive tumors.
|
28084344 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Based on the ROC curve of 80% with an area under the curve (AUC) of 0.78, expression of MCM-2 to diagnose high-grade CIN and invasive tumor resulted in sensitivity of 81%, specificity of 66%, a positive predictive value (PPV) of 86% and a negative predictive value (NPV) of 57%.
|
22493662 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Highly malignant tumors overexpress the minichromosome maintenance 2 (MCM2) protein in the nucleus, which is associated with advanced tumor grade, advanced stage, and poor prognosis.
|
29963273 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry was performed to analyze the expression of MCM2, Ki-67, Cyclin A and PHH3, which were correlated with the following clinicopathological parameters: clinical TNM, tumor grade, biological subtype, the presence of tumor infiltrating lymphocytes (TIL), pathological tumor response rate to the neoadjuvant therapy and patient survival.
|
31446607 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In tumors Mcm2 labeling was predominantly at the periphery with LIs ranging from 0.2-91.5%, which was significantly greater than Ki-67 LI (0.2-40.5%; P < 0.001).
|
11948116 |
2002 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In MCM2 deficient mice a different set of preferred breakage sites is identified that includes the tumor suppressor gene Tcf3, which is known to contribute to T-lymphocytic leukemias that arise in these mice, and the 45S rRNA gene repeats.
|
28045896 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, a high-level expression of MCM2 in either primary tumor or metastases of RCC predicted a shorter disease-free survival time, while a high-level expression of MCM4 or MCM6 in primary tumor was also associated with poorer disease-free survival.
|
29180899 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, these studies show that tumor types resulting from Mcm2 deficiency are strongly affected by interaction with both genetic background and p53.
|
20440269 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In breast cancers, increasing tumour grade is associated with increased Ki67, Mcm2 and geminin expression.
|
16278669 |
2005 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased Ki67, Mcm2, and geminin levels were each significantly associated with arrested tumor differentiation (P < 0.0001) and aneuploidy (P < or = 0.01).
|
19920109 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ki67, Mcm2, geminin, and Aurora A and B are significantly associated with tumor grade and ploidy status (P < 0.0001).
|
17947481 |
2007 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Meanwhile, we analyzed the association between MCM2 protein expression and clinicopathological characteristics of LUSC patients, and found high expression of MCM2 protein was obviously associated with malign differentiated degree, advanced clinical stage, large tumor size, more lymph node metastasis and present distant metastasis.
|
30174440 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Notably, MCM2 and MCM3 expression levels were positively correlated with the DHX9 expression level in tumor samples and were associated with a poor prognosis in patients with osteosarcoma.
|
28460433 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nuclear expression of MCM2 was noted in tumor but not mitotic cells of all the MFHs and 26 (72.2%) of the BFHTs, the labeling indices (LIs) being 62.0% in the 28 ordinary types, 38.5% in the 10 myxoid types, and 11.2% in the BFHTs with significant difference.
|
12119552 |
2002 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Particularly, 11 proteins involved in tumor proliferation (MCM2, 4, 6, 7, and MSH2), metastasis (RCC2, CORO1C, CHD4, and IPO9), and cancer metabolism (PHGDH and TYMP) are identified as SCLC-specific proteins.
|
29888431 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with negative tumor MCM2 expression displayed a better survival time than those with positive MCM2 expression (P<0.05).
|
21947329 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Positive MCM2 and negative TIP30 expression were significantly associated with large tumor size, high TNM stage, invasion, lymph node metastasis and lack of surgical curability in SC/ASC and AC.
|
27748889 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of the present study was to analyze and compare the expression of Mcm-2 in normal oral mucosa (NM) and oral squamous cell carcinomas at tumor margins (TM), the tumor center (TC), and the invasive tumor front (ITF), with correlation of clinicopathologic features.
|
30359334 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combined analyses of TRIP13+RAD51+MCM2 showed the worse association for RFS (HR 2.25 (1.51-3.35) log rank p= 4.1e-05) and TRIP13+RAD51 for OS (HR 5.13 (0.6-44.17) log rank p=0.098) in ER+/HER2- tumors.
|
28968952 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of MCM2, MCM5 and MCM6 was significantly associated with gender (<i>P</i> = 0.00004, 0.00004, 0.008), tumor type (<i>P</i> < 0.00001, < 0.00001, 0.00001) and smoking history (<i>P</i> = 0.009, 0.00043, 0.002).
|
29151950 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of EGFR family members was examined by immunohistochemistry in 22 phyllodes tumors, and the results were evaluated together with immunohistochemical findings for proliferation markers Ki67 and BM28, and the tumor suppressor gene product p53.
|
11206334 |
2001 |